R.H. Dinel Investment Counsel Inc. Has $6.33 Million Holdings in Amgen Inc. $AMGN

R.H. Dinel Investment Counsel Inc. trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 14.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,325 shares of the medical research company’s stock after selling 3,200 shares during the quarter. Amgen makes up approximately 4.6% of R.H. Dinel Investment Counsel Inc.’s portfolio, making the stock its 8th biggest holding. R.H. Dinel Investment Counsel Inc.’s holdings in Amgen were worth $6,325,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Board of the Pension Protection Fund bought a new position in Amgen in the 4th quarter valued at $26,000. Howard Hughes Medical Institute bought a new position in shares of Amgen in the second quarter worth $32,000. Olistico Wealth LLC purchased a new stake in shares of Amgen in the fourth quarter worth $33,000. Cloud Capital Management LLC purchased a new stake in shares of Amgen in the third quarter worth $34,000. Finally, Saranac Partners Ltd bought a new stake in Amgen during the third quarter valued at $37,000. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on AMGN. Leerink Partners restated a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Truist Financial upped their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Finally, Royal Bank Of Canada raised their target price on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Performance

NASDAQ AMGN opened at $348.77 on Monday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock’s 50-day simple moving average is $362.59 and its two-hundred day simple moving average is $330.59. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a market capitalization of $188.01 billion, a price-to-earnings ratio of 24.51, a PEG ratio of 3.46 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the business earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.